PYXS Pyxis Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782223 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin97.1%
Operating margin-554.1%
Net margin-478.9%
FCF margin-358.7%
EBITDA margin-535.6%
Returns
ROE-62.8%
ROA-46.7%
ROIC (approx.)-65.0%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio7.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.86M | $16.15M |
| Cost of revenue | $2.39M | $475,000 |
| Gross profit | $11.47M | $15.67M |
| R&D expense | $73.70M | $58.75M |
| SG&A expense | $22.19M | $25.42M |
| Operating income | -$84.42M | -$89.46M |
| Pretax income | -$78.23M | -$79.50M |
| Income tax | $1.39M | -$2.16M |
| Net income | -$79.62M | -$77.33M |
| EBITDA | -$79.91M | -$86.48M |
| EPS (basic) | -1.28 | -1.32 |
| EPS (diluted) | -1.28 | -1.32 |
| Weighted avg. shares (diluted) | 62.14M | 58.45M |
| Balance sheet | ||
| Cash & equivalents | $15.42M | $19.47M |
| Short-term investments | $51.44M | $107.46M |
| Current assets | $72.11M | $132.44M |
| PP&E, net | $8.00M | $9.90M |
| Intangibles | $0 | $2.60M |
| Total assets | $91.52M | $157.18M |
| Current liabilities | $21.13M | $17.68M |
| Total liabilities | $38.11M | $36.43M |
| Shareholders' equity | $53.41M | $120.75M |
| Shares outstanding | 62.69M | 59.97M |
| Cash flow statement | ||
| Operating cash flow | -$63.50M | -$57.67M |
| Capital expenditure | $9,000 | $237,000 |
| Free cash flow | -$63.51M | -$57.91M |
| Investing cash flow | $58.86M | $8.15M |
| Financing cash flow | $594,000 | $59.33M |
| Depreciation & amortization | $4.51M | $2.98M |
| Stock-based compensation | $11.80M | $12.95M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.